Fibrolamellar hepatocellular carcinoma: current clinical perspectives

Clicks: 258
ID: 6653
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #82 of 194 articles by views in journal of hepatocellular carcinoma

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 194 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Fibrolamellar hepatocellular carcinoma: current clinical perspectives Kelly J Lafaro,1 Timothy M Pawlik2 1Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, 2Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA Abstract: Fibrolamellar carcinoma (FLC) is a variant of hepatocellular carcinoma (HCC), which comprises ~1%–9% of all HCCs. Although FLC is a variant of HCC, it is distinct from HCC in that it most often affects younger patients (10–35 years of age) with no underlying liver disease. FLC often presents with vague abdominal pain, nausea, abdominal fullness, malaise, and weight loss. Surgery is the current mainstay of treatment for FLC and remains the only potentially curative option. While FLCs are considered less responsive to chemotherapy than their classic HCC counterparts, there have been suggestions that multimodality treatments may be effective, especially in advanced cases. Further research is necessary to determine effective systemic therapies as an adjunct to surgery for FLC. Keywords: hepatocellular carcinoma, fibrolamellar, hepatocyte paraffin I, locoregional therapy
Reference Key
kelly2015fibrolamellarjournal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kelly J Lafaro;Timothy M Pawlik and
Journal journal of hepatocellular carcinoma
Year 2015
DOI
10.2147/JHC.S75153
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.